MedTrace Logo

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2026-06-08

No results posted yet for this study

Summary

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

Conditions

  • Desmoid
  • Desmoid Tumor

Interventions

DRUG

AL102

AL102 is an inhibitor of gamma secretase-mediated Notch signaling.

OTHER

Placebo

Placebo to match AL102

Sponsors & Collaborators

  • Immunome, Inc.

    lead INDUSTRY

Principal Investigators

  • Mrinal Gounder, MD · MSKCC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2025-12-03
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Poland
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871282 on ClinicalTrials.gov